Compare Sana Biotechnology Inc (SANA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs VF Corp — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while VF Corp trades at $14.65 (market cap $5.81B). The key difference: VF Corp is far larger — about 5.1× Sana Biotechnology Inc's market cap, and VF Corp pays a 2.44% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VFC | |
|---|---|---|
Market Cap | $1.13B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $21.55 |
52-Week Low | $2.68 | $12.21 |
Enterprise Value | $1.05B | $10.09B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
VFC stock trades at $14.69, down 1.41% on the day, reflecting ongoing pressure from recent earnings misses and weak Vans brand performance. Technical indicators are bearish, with the price near key support at $14.00. Fundamentally, revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company is focused on deleveraging, with debt-to-asset ratio improving to 42.42% in 2025.
The outlook remains challenging due to brand-specific headwinds and macro pressures, but cost controls and a raised fiscal 2027 revenue outlook offer some optimism. Risks include persistent Vans weakness and consumer sentiment, while the consensus price target of $17.44 suggests modest upside if turnaround efforts gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
